# C-SMART (NCT04534725)

> COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04534725
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Cancer; Covid19; Respiratory Viral Infection
- Interventions: Interferon alfa; Selinexor; Lenzilumab
- Enrollment: 441
- Primary outcome: Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)
- Primary outcome: incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing
- Primary outcome: incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .
- Primary outcome: incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testing
- Primary outcome: incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical records
- Primary outcome: time to clinical improvement or discharge from hospital assessed using medical records

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=c-smart-nct04534725